Omalizumab induced lichenoid drug eruption triggered by sun exposure
Yükleniyor...
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Blackwell Publishing Inc.
Erişim Hakkı
info:eu-repo/semantics/embargoedAccess
Özet
Dear Editor Omalizumab is a humanized monoclonal antibody against human immunoglobulin E that is mainly indicated in asthma, allergic rhinitis, chronic spontaneous urticaria and is being increasingly used for other dermatological diseases, including atopic dermatitis, mastocytosis, hyper-IgE syndrome, and bullous pemphigoid.1,2 Rare cutaneous side effects, such as itching, skin rash, urticaria, and photosensitivity, have been reported to be associated with omalizumab use.
Açıklama
*Kemeriz, Funda ( Aksaray, Yazar ) *Ordu, Melike ( Aksaray, Yazar )
Anahtar Kelimeler
Antihistaminic Agent, Omalizumab, Steroid
Kaynak
Dermatologic Therapy
WoS Q Değeri
Q3
Scopus Q Değeri
Q1
Cilt
33
Sayı
4
